{
    "doc_id": "mmlu_279_deepseek-ai_DeepSeek-V3",
    "metadata": {
        "model_id": "deepseek-ai/DeepSeek-V3",
        "subject": "virology",
        "correct_answer": "Seroconverters"
    },
    "raw_text": {
        "question": "The median survival time to AIDS and death was established by following:",
        "response": "The median survival time to AIDS and death is typically established through longitudinal cohort studies, where a group of individuals (often those diagnosed with HIV) is followed over time to track the progression of the disease. The median survival time is the point at which 50% of the study population has progressed to AIDS or died, and 50% are still alive or have not yet progressed to AIDS.\n\n### Key Steps in Establishing Median Survival Time:\n1. **Study Design**: A cohort of individuals with HIV is identified and enrolled in the study. This cohort is followed over a period of years, often decades, to monitor disease progression and survival.\n\n2. **Data Collection**: Regular follow-ups are conducted to collect data on the health status of participants, including the development of AIDS-defining illnesses and mortality.\n\n3. **Analysis**: Survival analysis techniques, such as Kaplan-Meier survival curves, are used to estimate the median survival time. The Kaplan-Meier method accounts for censored data (e.g., participants who are lost to follow-up or who have not yet reached the endpoint of interest).\n\n4. **Median Survival Time**: The median survival time is determined by identifying the time point at which 50% of the cohort has experienced the event of interest (e.g., progression to AIDS or death).\n\n### Historical Context:\n- **Pre-HAART Era (Before 1996)**: Before the introduction of highly active antiretroviral therapy (HAART), the median survival time from HIV infection to AIDS was approximately 10 years, and the median survival time from AIDS to death was about 1-2 years.\n  \n- **Post-HAART Era (After 1996)**: With the advent of HAART, the median survival time has significantly increased. Many individuals with HIV who are on effective antiretroviral therapy can now expect to live near-normal lifespans, and the progression to AIDS has been dramatically reduced.\n\n### Factors Influencing Survival Time:\n- **Access to Treatment**: Early initiation of antiretroviral therapy (ART) significantly improves survival.\n- **Adherence to Treatment**: Consistent adherence to ART is crucial for maintaining viral suppression and preventing disease progression.\n- **Co-infections and Comorbidities**: The presence of co-infections (e.g., hepatitis B or C) or comorbidities (e.g., cardiovascular disease) can affect survival.\n- **Socioeconomic Factors**: Access to healthcare, socioeconomic status, and social support also play a role in survival outcomes.\n\n### Conclusion:\nThe median survival time to AIDS and death is a critical measure in understanding the natural history of HIV and the impact of treatment. Advances in antiretroviral therapy have transformed HIV from a fatal disease to a manageable chronic condition for many individuals."
    },
    "nodes": [
        {
            "id": "ctx0",
            "annotation": false,
            "start": 0,
            "end": 72,
            "label": "context",
            "text": "The median survival time to AIDS and death was established by following:",
            "source": "question"
        },
        {
            "id": "resp0",
            "annotation": false,
            "start": 0,
            "end": 230,
            "label": "fact",
            "text": "The median survival time to AIDS and death is typically established through longitudinal cohort studies, where a group of individuals (often those diagnosed with HIV) is followed over time to track the progression of the disease. ",
            "source": "response"
        },
        {
            "id": "resp1",
            "annotation": false,
            "start": 230,
            "end": 398,
            "label": "fact",
            "text": "The median survival time is the point at which 50% of the study population has progressed to AIDS or died, and 50% are still alive or have not yet progressed to AIDS.\n\n",
            "source": "response"
        },
        {
            "id": "resp2",
            "annotation": false,
            "start": 398,
            "end": 450,
            "label": "planning",
            "text": "### Key Steps in Establishing Median Survival Time:\n",
            "source": "response"
        },
        {
            "id": "resp3",
            "annotation": false,
            "start": 450,
            "end": 545,
            "label": "planning",
            "text": "1. **Study Design**: A cohort of individuals with HIV is identified and enrolled in the study. ",
            "source": "response"
        },
        {
            "id": "resp4",
            "annotation": false,
            "start": 545,
            "end": 654,
            "label": "fact",
            "text": "This cohort is followed over a period of years, often decades, to monitor disease progression and survival.\n\n",
            "source": "response"
        },
        {
            "id": "resp5",
            "annotation": false,
            "start": 654,
            "end": 834,
            "label": "fact",
            "text": "2. **Data Collection**: Regular follow-ups are conducted to collect data on the health status of participants, including the development of AIDS-defining illnesses and mortality.\n\n",
            "source": "response"
        },
        {
            "id": "resp6",
            "annotation": false,
            "start": 834,
            "end": 966,
            "label": "fact",
            "text": "3. **Analysis**: Survival analysis techniques, such as Kaplan-Meier survival curves, are used to estimate the median survival time. ",
            "source": "response"
        },
        {
            "id": "resp7",
            "annotation": false,
            "start": 966,
            "end": 1119,
            "label": "fact",
            "text": "The Kaplan-Meier method accounts for censored data (e.g., participants who are lost to follow-up or who have not yet reached the endpoint of interest).\n\n",
            "source": "response"
        },
        {
            "id": "resp8",
            "annotation": false,
            "start": 1119,
            "end": 1321,
            "label": "fact",
            "text": "4. **Median Survival Time**: The median survival time is determined by identifying the time point at which 50% of the cohort has experienced the event of interest (e.g., progression to AIDS or death).\n\n",
            "source": "response"
        },
        {
            "id": "resp9",
            "annotation": false,
            "start": 1321,
            "end": 1345,
            "label": "planning",
            "text": "### Historical Context:\n",
            "source": "response"
        },
        {
            "id": "resp10",
            "annotation": false,
            "start": 1345,
            "end": 1533,
            "label": "fact",
            "text": "- **Pre-HAART Era (Before 1996)**: Before the introduction of highly active antiretroviral therapy (HAART), the median survival time from HIV infection to AIDS was approximately 10 years, ",
            "source": "response"
        },
        {
            "id": "resp11",
            "annotation": false,
            "start": 1533,
            "end": 1605,
            "label": "fact",
            "text": "and the median survival time from AIDS to death was about 1-2 years.\n  \n",
            "source": "response"
        },
        {
            "id": "resp12",
            "annotation": false,
            "start": 1605,
            "end": 1720,
            "label": "fact",
            "text": "- **Post-HAART Era (After 1996)**: With the advent of HAART, the median survival time has significantly increased. ",
            "source": "response"
        },
        {
            "id": "resp13",
            "annotation": false,
            "start": 1720,
            "end": 1836,
            "label": "fact",
            "text": "Many individuals with HIV who are on effective antiretroviral therapy can now expect to live near-normal lifespans, ",
            "source": "response"
        },
        {
            "id": "resp14",
            "annotation": false,
            "start": 1836,
            "end": 1896,
            "label": "fact",
            "text": "and the progression to AIDS has been dramatically reduced.\n\n",
            "source": "response"
        },
        {
            "id": "resp15",
            "annotation": false,
            "start": 1896,
            "end": 1935,
            "label": "planning",
            "text": "### Factors Influencing Survival Time:\n",
            "source": "response"
        },
        {
            "id": "resp16",
            "annotation": false,
            "start": 1935,
            "end": 2044,
            "label": "fact",
            "text": "- **Access to Treatment**: Early initiation of antiretroviral therapy (ART) significantly improves survival.\n",
            "source": "response"
        },
        {
            "id": "resp17",
            "annotation": false,
            "start": 2044,
            "end": 2183,
            "label": "fact",
            "text": "- **Adherence to Treatment**: Consistent adherence to ART is crucial for maintaining viral suppression and preventing disease progression.\n",
            "source": "response"
        },
        {
            "id": "resp18",
            "annotation": false,
            "start": 2183,
            "end": 2346,
            "label": "fact",
            "text": "- **Co-infections and Comorbidities**: The presence of co-infections (e.g., hepatitis B or C) or comorbidities (e.g., cardiovascular disease) can affect survival.\n",
            "source": "response"
        },
        {
            "id": "resp19",
            "annotation": false,
            "start": 2346,
            "end": 2478,
            "label": "fact",
            "text": "- **Socioeconomic Factors**: Access to healthcare, socioeconomic status, and social support also play a role in survival outcomes.\n\n",
            "source": "response"
        },
        {
            "id": "resp20",
            "annotation": false,
            "start": 2478,
            "end": 2494,
            "label": "planning",
            "text": "### Conclusion:\n",
            "source": "response"
        },
        {
            "id": "resp21",
            "annotation": false,
            "start": 2494,
            "end": 2632,
            "label": "reasoning",
            "text": "The median survival time to AIDS and death is a critical measure in understanding the natural history of HIV and the impact of treatment. ",
            "source": "response"
        },
        {
            "id": "resp22",
            "annotation": false,
            "start": 2632,
            "end": 2764,
            "label": "conclusion",
            "text": "Advances in antiretroviral therapy have transformed HIV from a fatal disease to a manageable chronic condition for many individuals.",
            "source": "response"
        }
    ],
    "edges": [
        {
            "id": "e0",
            "from_node_id": "ctx0",
            "to_node_id": "resp0",
            "label": "reason:fact-detail"
        },
        {
            "id": "e1",
            "from_node_id": "resp0",
            "to_node_id": "resp1",
            "label": "reason:fact-detail"
        },
        {
            "id": "e2",
            "from_node_id": "resp0",
            "to_node_id": "resp2",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e3",
            "from_node_id": "resp1",
            "to_node_id": "resp2",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e4",
            "from_node_id": "resp2",
            "to_node_id": "resp3",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e5",
            "from_node_id": "resp3",
            "to_node_id": "resp4",
            "label": "reason:fact-detail"
        },
        {
            "id": "e6",
            "from_node_id": "resp3",
            "to_node_id": "resp5",
            "label": "reason:plan-step"
        },
        {
            "id": "e7",
            "from_node_id": "resp4",
            "to_node_id": "resp5",
            "label": "reason:fact-detail"
        },
        {
            "id": "e8",
            "from_node_id": "resp5",
            "to_node_id": "resp6",
            "label": "reason:plan-step"
        },
        {
            "id": "e9",
            "from_node_id": "resp6",
            "to_node_id": "resp7",
            "label": "reason:fact-detail"
        },
        {
            "id": "e10",
            "from_node_id": "resp1",
            "to_node_id": "resp8",
            "label": "reason:fact-detail"
        },
        {
            "id": "e11",
            "from_node_id": "resp6",
            "to_node_id": "resp8",
            "label": "reason:fact-detail"
        },
        {
            "id": "e12",
            "from_node_id": "resp2",
            "to_node_id": "resp9",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e13",
            "from_node_id": "resp3",
            "to_node_id": "resp9",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e14",
            "from_node_id": "resp4",
            "to_node_id": "resp9",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e15",
            "from_node_id": "resp5",
            "to_node_id": "resp9",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e16",
            "from_node_id": "resp6",
            "to_node_id": "resp9",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e17",
            "from_node_id": "resp7",
            "to_node_id": "resp9",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e18",
            "from_node_id": "resp8",
            "to_node_id": "resp9",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e19",
            "from_node_id": "resp8",
            "to_node_id": "resp10",
            "label": "reason:fact-detail"
        },
        {
            "id": "e20",
            "from_node_id": "resp9",
            "to_node_id": "resp10",
            "label": "reason:plan-step"
        },
        {
            "id": "e21",
            "from_node_id": "resp10",
            "to_node_id": "resp11",
            "label": "reason:fact-detail"
        },
        {
            "id": "e22",
            "from_node_id": "resp11",
            "to_node_id": "resp12",
            "label": "reason:fact-detail"
        },
        {
            "id": "e23",
            "from_node_id": "resp12",
            "to_node_id": "resp13",
            "label": "reason:fact-detail"
        },
        {
            "id": "e24",
            "from_node_id": "resp12",
            "to_node_id": "resp14",
            "label": "reason:fact-detail"
        },
        {
            "id": "e25",
            "from_node_id": "resp13",
            "to_node_id": "resp14",
            "label": "reason:fact-detail"
        },
        {
            "id": "e26",
            "from_node_id": "resp9",
            "to_node_id": "resp15",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e27",
            "from_node_id": "resp10",
            "to_node_id": "resp15",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e28",
            "from_node_id": "resp12",
            "to_node_id": "resp15",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e29",
            "from_node_id": "resp14",
            "to_node_id": "resp16",
            "label": "reason:fact-detail"
        },
        {
            "id": "e30",
            "from_node_id": "resp15",
            "to_node_id": "resp16",
            "label": "reason:plan-step"
        },
        {
            "id": "e31",
            "from_node_id": "resp15",
            "to_node_id": "resp17",
            "label": "reason:plan-step"
        },
        {
            "id": "e32",
            "from_node_id": "resp16",
            "to_node_id": "resp17",
            "label": "reason:fact-detail"
        },
        {
            "id": "e33",
            "from_node_id": "resp15",
            "to_node_id": "resp18",
            "label": "reason:fact-detail"
        },
        {
            "id": "e34",
            "from_node_id": "resp15",
            "to_node_id": "resp19",
            "label": "reason:fact-detail"
        },
        {
            "id": "e35",
            "from_node_id": "resp16",
            "to_node_id": "resp19",
            "label": "reason:fact-detail"
        },
        {
            "id": "e36",
            "from_node_id": "resp17",
            "to_node_id": "resp19",
            "label": "reason:fact-detail"
        },
        {
            "id": "e37",
            "from_node_id": "resp18",
            "to_node_id": "resp19",
            "label": "reason:fact-detail"
        },
        {
            "id": "e38",
            "from_node_id": "resp9",
            "to_node_id": "resp20",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e39",
            "from_node_id": "resp15",
            "to_node_id": "resp20",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e40",
            "from_node_id": "resp0",
            "to_node_id": "resp21",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e41",
            "from_node_id": "resp1",
            "to_node_id": "resp21",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e42",
            "from_node_id": "resp8",
            "to_node_id": "resp21",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e43",
            "from_node_id": "resp10",
            "to_node_id": "resp21",
            "label": "reason:fact-detail"
        },
        {
            "id": "e44",
            "from_node_id": "resp12",
            "to_node_id": "resp21",
            "label": "reason:fact-detail"
        },
        {
            "id": "e45",
            "from_node_id": "resp16",
            "to_node_id": "resp21",
            "label": "reason:fact-detail"
        },
        {
            "id": "e46",
            "from_node_id": "resp17",
            "to_node_id": "resp21",
            "label": "reason:fact-detail"
        },
        {
            "id": "e47",
            "from_node_id": "resp18",
            "to_node_id": "resp21",
            "label": "reason:fact-detail"
        },
        {
            "id": "e48",
            "from_node_id": "resp19",
            "to_node_id": "resp21",
            "label": "reason:fact-detail"
        },
        {
            "id": "e49",
            "from_node_id": "resp12",
            "to_node_id": "resp22",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e50",
            "from_node_id": "resp13",
            "to_node_id": "resp22",
            "label": "reason:fact-detail"
        },
        {
            "id": "e51",
            "from_node_id": "resp14",
            "to_node_id": "resp22",
            "label": "reason:fact-detail"
        },
        {
            "id": "e52",
            "from_node_id": "resp21",
            "to_node_id": "resp22",
            "label": "reason:premise-conclusion"
        }
    ]
}